Inclusion Criteria:

- Eligibility

- Patients who are receiving single agent anti-VEGF therapy

- Signed written informed consent

- Patients with measurable pulmonary malignancy (primary or metastatic) as determined
by RECIST will undergo assessment of pulmonary function

- Patients with a known allergy to intravenous contrast used in fluorescein and
indocyanine green angiography will be exempt from these investigations but will
undergo other study assessments

Exclusion Criteria:

- None